Benedikt M Schaarschmidt
Overview
Explore the profile of Benedikt M Schaarschmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
466
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hamacher R, Pabst K, Cheung P, Heilig C, Hullein J, Liffers S, et al.
J Nucl Med
. 2024 Jan;
65(2):252-257.
PMID: 38176718
Fibroblast activation protein α (FAPα) is expressed at high levels in several types of tumors. Here, we report the expression pattern of FAPα in solitary fibrous tumor (SFT) and its...
12.
Kessler L, Hirmas N, Pabst K, Hamacher R, Ferdinandus J, Schaarschmidt B, et al.
J Nucl Med
. 2023 Nov;
64(12):1910-1917.
PMID: 37973185
The fibroblast activation protein (FAP) is highly expressed on carcinoma-associated fibroblasts in the stroma of pancreatic cancer and thus is a promising target for imaging and therapy. Preliminary data on...
13.
Weber M, Pettersson O, Seifert R, Schaarschmidt B, Fendler W, Rischpler C, et al.
Eur J Nucl Med Mol Imaging
. 2023 Nov;
51(3):841-851.
PMID: 37947848
Background: Historically, patient selection for peptide receptor radionuclide therapy (PRRT) has been performed by virtue of somatostatin receptor scintigraphy (SRS). In recent years, somatostatin receptor positron emission tomography (SSTR-PET) has...
14.
Milosevic A, Styczen H, Haubold J, Kessler L, Grueneisen J, Li Y, et al.
Nucl Med Commun
. 2023 Oct;
44(12):1106-1113.
PMID: 37823259
Purpose: To evaluate a correlation between an MRI-specific marker for cellular density [apparent diffusion coefficient (ADC)] and the expression of Somatostatin Receptors (SSTR) in patients with meningioma of the skull...
15.
Meetschen M, Bucker A, Nikolaou K, Salhofer L, Zensen S, Schaarschmidt B, et al.
Dtsch Arztebl Int
. 2023 Sep;
120(33-34):553-554.
PMID: 37732592
No abstract available.
16.
Slama A, Schaarschmidt B, Okumus O, Herrmann K, Aigner C, Collaud S, et al.
Quant Imaging Med Surg
. 2023 Jul;
13(7):4716-4722.
PMID: 37456303
The use of Isolated lung perfusion (ILP), combined with medical imaging modalities such as positron emission tomography-computed tomography (PET/CT), provides real-time visualization of tumors in ventilated and perfused vital lung...
17.
Steinberg H, Auer T, Gebauer B, Kloeckner R, Sieren M, Minko P, et al.
Eur J Radiol
. 2023 Jun;
165:110892.
PMID: 37269571
Purpose: The purpose of this study was to assess the efficacy of transarterial embolization in COVID-19 patients with an arterial bleeding and to investigate differences between various patient groups concerning...
18.
Mei R, Kessler L, Pabst K, Weber M, Schmidkonz C, Rischpler C, et al.
J Nucl Med
. 2023 May;
64(7):1043-1048.
PMID: 37230530
Ga-fibroblast activation protein inhibitors (FAPIs) are promising radiotracers for cancer imaging, with emerging data in the recent years. Nonetheless, the interobserver agreement on Ga-FAPI PET/CT study interpretations in cancer patients...
19.
Pabst K, Trajkovic-Arsic M, Cheung P, Ballke S, Steiger K, Bartel T, et al.
J Nucl Med
. 2023 Apr;
64(7):1049-1055.
PMID: 37024301
Management of cholangiocarcinoma is among other factors critically determined by accurate staging. Here, we aimed to assess the accuracy of PET/CT with the novel cancer fibroblast-directed Ga-fibroblast activation protein (FAP)...
20.
Maric I, Weber M, Prochnow A, Schmitz J, Unger N, Schaarschmidt B, et al.
J Nucl Med
. 2023 Feb;
64(6):885-891.
PMID: 36732054
We aim to evaluate the efficacy and safety of I-metaiodobenzylguanidine (MIBG) dosimetry-guided high-activity I-MIBG therapy of advanced pheochromocytoma or neuroblastoma. Fourteen patients with advanced pheochromocytoma or neuroblastoma, age 9-69 y,...